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The American Heart Association estimates that one 
in five deaths from cardiovascular disease are directly 
linked to cigarette smoking. Individuals who smoke are 
two to six times more likely to develop coronary artery 
disease than nonsmokers. However, individuals who 
quit smoking will reduce their risk to levels equivalent 
to those of a nonsmoker within three years. 
Exposure to cigarette smoke is an established risk fac-
tor for coronary heart disease in both Western and Asian 
countries. The multivariate relative risk of coronary heart 
disease mortality for current smokers was 1.8-3.7 com-
pared to nonsmokers.
1) Poor prognosis in smokers re-
sults from: 1) induction of hypercoagulability due to in-
creased platelet activation, dyslipidemia, and endothe-
lial dysfunction; 2) increased catecholamine release lead-
ing to increased heart rate, blood pressure, coronary 
vasoconstriction, and even arrhythmogenic effect; and 
3) reduction in oxygen delivery due to increased carbon 
monoxide levels.
2) 
The term of “smoker’s paradox” has been coined by 
Barbash et al.
3) who reported better outcomes among 
the smokers receiving thrombolytic therapy for acute 
myocardial infarction. Similarly, Cohen et al.
4) reported 
that cigarette smoking was associated with a lower rate 
of subsequent target lesion revascularization in patients 
undergoing percutaneous coronary intervention (PCI). 
Hasdai et al.
5) reported that current smokers during an 
index percutaneous intervention had fewer adverse 
events in the univariable analysis than the nonsmokers 
and former smokers. This improved can be explained 
in part by better covariables such as younger age or a more 
favorable clinical and angiographic profile. Therefore, 
this term may be misleading.
6) 
Clopidogrel, an inhibitor of the platelet P2Y12 ade-
nosine diphosphate receptor, improves prognosis in pa-
tients with acute coronary syndrome (ACS). However, 
there is significant response variability and a diminish-
ed clopidogrel response is associated with an increased 
risk of ischemic events.
7) Smoking induces cytochrome 
P450 1A2 (CYP1A2), a hepatic enzyme involved in the 
metabolism of clopidogrel. Clopidogrel shows better in-
hibition of platelet aggregation in smokers than non-
smokers,
8) and smokers are less likely to be hyporespon-
ders than nonsmokers.
9) 
In this issue of the Journal, Cho et al.
10) investigated 
the association between smoking status and post-clo-
pidogrel platelet reactivity in patients with acute myo-
cardial infarction. Differences in the clinical situation 
and timing of the platelet test could explain the differ-
ences with the Bliden study.
8) The decreases in CYP1A2 
activity induced by smoking may also disappear after 
three days.   
The CHARISMA (Clopidogrel for High Atheroth-
rombotic Risk and Ischemic Stabilization, Management, 
and Avoidance) trial compared long-term clopidogrel 
75 mg/day vs. placebo in patients at high risk for car-
diovascular events, and clopidogrel significantly reduc-
ed mortality in smokers but not in former or never-
smokers.
11) In addition to CYP1A2 activation by smok-
ing, smokers may simply be a higher-risk group because 
of enhanced platelet activity and therefore benefit more 
from antithrombotic intervention. The Clopidogrel as 
Adjunctive Reperfusion Therapy-Thrombolysis In Myo-
cardial Infarction 28 (CLARITY-TIMI 28) trial com-
pared the effect of clopidogrel on angiographic and cli-
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nical outcomes in 3,429 ST elevation myocardial infarc-
tion patients by smoking intensity: not current smokers 
(n=1,732), and smokers of 1 to 9 (n=206), 10 to 19 
(n=354), 20 to 29 (n=715), and ≥30 cigarettes/day 
(n=422). Clopidogrel reduced the primary end point 
of a closed infarct-related artery or death/myocardial 
infarction, particularly among those who smoked ≥
10 cigarettes/day.
12) The CURRENT-OASIS 7 (Clopi-
dogrel Optimal Loading Dose Usage to Reduce Recur-
rent Events/Optimal Antiplatelet Strategy for Interven-
tions) trial, which tested high-dose vs. usual-dose clo-
pidogrel in ACS patients undergoing PCI, showed that 
smokers (vs. nonsmokers) had significant benefit with 
the higher clopidogrel dose. 
Smoking increases the risk for cardiovascular events 
and mortality in patients with established cardiovas-
cular disease, but clopidogrel treatment may be more 
effective in smokers. Therefore, the interaction of smok-
ing with acute myocardial infarction deserves further 
study in more patients using designs that show fewer 
time limitations.   
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